Maastricht University
maastrichtuniversity.nlMatched: Maastricht University Medical Center · Maastricht University
Total trials
940
Active
109
Phase 3
26
Total enrollment
247,979
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 24 of 24 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Fluorometholone 0.1% Oph Susp | — | — | — | — | — | 1 | |
| Dexamethasone 0.1% ophthalmic suspension | — | — | — | — | — | 1 | |
| Adalimumab | — | — | — | — | — | 1 | |
| standard step-up care | — | — | — | — | — | 1 | |
| 4.8 g/m^2/day NaPB | — | — | — | — | — | 1 | |
| 4.8 g/m^2/day placebo | — | — | — | — | — | 1 | |
| 5FU-Calcipotriol | — | — | — | — | — | 1 | |
| 5-FU 50 MG/ML Topical Cream | — | — | — | — | — | 1 | |
| Cobicistat | — | — | — | — | — | 1 | |
| Fluconazole | — | — | — | — | 2 | ||
| Osimertinib & febuxostat | — | — | — | — | — | 1 | |
| Tarlatamab | — | — | — | — | — | 1 | |
| CP-506 | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 1 | |
| Immune checkpoint inhibitor | — | — | — | — | — | 1 | |
| Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab | — | — | — | — | — | 1 | |
| Cannabis | — | — | — | — | — | 1 | |
| Knaster Hemp | — | — | — | — | — | 1 | |
| Biobanking of biomaterial for future genetic research. | — | — | — | — | — | 1 | |
| Vismodegib | — | — | — | — | — | 1 | |
| Sonidegib | — | — | — | — | — | 1 | |
| Isolation of tumor DNA | — | — | — | — | — | 1 | |
| Psilocybin | — | — | — | — | — | 1 | |
| Venous blood sampling prior to CCTA. | — | — | — | — | — | 1 |
Next readouts
- 2024-03
- 2024-05
- 2025-10
- 2025-12
- 2025-12
- 2026-04-22
- 2026-06
- 2026-06-01
- 2026-11-01
- 2026-12-31
Top conditions
- Obesity54
- Healthy21
- Overweight and Obesity19
- Insulin Resistance19
- Breast Cancer18
- Atrial Fibrillation16
- Overweight15
- Type 2 Diabetes15
Frequently asked questions about Maastricht University
- How many clinical trials does Maastricht University have on ClinicalTrials.gov?
- Maastricht University is listed as the lead sponsor on 940 clinical trials in ClinicalTrials.gov, 109 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Maastricht University's trials are in Phase 3?
- 26 of Maastricht University's trials are in Phase 3, spread across 24 active drug programs.
- What therapeutic areas does Maastricht University focus on?
- Maastricht University's most-studied conditions on ClinicalTrials.gov are Obesity, Healthy, Overweight and Obesity, Insulin Resistance, Breast Cancer.
- When are Maastricht University's next clinical trial readouts?
- Maastricht University has 10 upcoming primary-completion readouts tracked here; the soonest is “Biobank Clinical Genetics Maastricht (KG01)”, expected around 2024-03.